Participated · Seed · May 2026

Violet Therapeutics uses its proprietary CONNECT platform to map cellular interaction networks at scale and identify novel therapeutic targets implicated in neuroinflammation and neurodegeneration. Its lead program is a small-molecule candidate targeting EphB3, a receptor tyrosine kinase implicated in microglia–astrocyte signaling and synaptic loss. The company is preclinical-stage and plans IND-enabling studies for the EphB3 program, funded in part by the recently closed $4.75M seed extension. Violet was founded by Mass General Brigham Ventures with researchers from Brigham and Women’s Hospital and is based in Cambridge, MA. The company aims to build a pipeline of first-in-class CNS therapies that prevent synapse loss and restore synaptic function across neurodegenerative diseases.

Participated · Series A · Sep 2025

Alchemab Therapeutics is a clinical-stage biotech founded in 2019 that uses its Resiliome™ platform—combining one of the world’s largest fully human antibody databases with AI and lab validation—to identify naturally occurring protective antibodies from disease-resilient individuals. The company has generated a pipeline of first- and best-in-class antibody assets, including ATLX-1282, a first-in-class therapeutic in clinical development for ALS that was licensed to Eli Lilly. Alchemab plans to expand its proprietary antibody dataset from about 500 million sequences to over one billion and to advance additional candidates into clinical development. The company’s platform integrates deep sequencing, AI-derived algorithms, and laboratory validation to characterise candidate antibodies. Alchemab has raised a total of £109 million in Series A financing to date and lists investors such as SV Health Investors, the Dementia Discovery Fund, RA Capital, DCVC Bio, Eli Lilly, Lightstone Ventures, Ono Venture Investment, and Camford Partners. The recent £25 million Series A extension led by the British Business Bank is intended to accelerate its clinical pipeline and database growth.

Participated · Series A · Jul 2024

AIRNA develops RNA‑editing medicines using a proprietary platform founded on academic research to precisely edit target RNA for both rare and common diseases. Its lead program, AIR‑001, is designed to repair the most common harmful SERPINA1 (PiZ) mutation in alpha‑1 antitrypsin deficiency (AATD) to restore functional M‑AAT production, with subcutaneous dosing and a focus on potency, durability, and safety. The company plans to file a clinical trial application for AIR‑001 in 2H 2025 and advance the candidate into a Phase 1/2 study. Proceeds from the recent financing will also fund development of a pipeline targeting cardiometabolic and other diseases by introducing beneficial genetic variants or repairing harmful ones. AIRNA cites research origins from University of Tübingen and Stanford co‑founders and maintains headquarters in Cambridge, MA, with research operations in Tübingen, Germany. AIRNA is developing RNA editing therapeutics via its RESTORE+ platform, which optimizes oligonucleotide sequence, chemistry, and delivery for precise RNA editing. Its lead product candidate is positioned as a potential best-in-class treatment for alpha-1 antitrypsin deficiency (AATD). The company is advancing a pipeline of candidates to address multiple diseases with high unmet need. AIRNA plans to bring its first drug candidate to the clinic next year and will use Series A proceeds to advance that program and further develop the platform. The company launched with backing from ARCH Venture Partners based on research by academic co-founders Thorsten Stafforst and Jin Billy Li. AIRNA is headquartered in Cambridge, MA, with research operations in Tübingen, Germany, and has raised a total of $90 million in Series A funding. AIRNA emerged from stealth to develop a new class of RNA editing therapeutics built on its RESTORE+ platform, which programs oligonucleotides to recruit endogenous ADAR for precise RNA modifications. The company’s scientific founders were among the first to publish ADAR-mediated RNA editing and the use of oligonucleotides to recruit endogenous ADAR for targeted editing. AIRNA is advancing a pipeline of candidates by optimizing sequence, chemistry, and delivery to achieve precise, efficient, and safe RNA editing. Its initial development program is a candidate to treat the inherited genetic disease alpha-1 antitrypsin deficiency (AATD), and the company is pursuing additional proprietary programs for prevalent diseases with high unmet need. AIRNA says its approach enables medicines that can be conveniently re-dosed and manufactured for large patient populations. The company is headquartered in Cambridge, MA, with research operations in Tübingen, Germany.

Participated · Series A · Jun 2023

Mozart Therapeutics develops CD8 Treg modulators to create disease-modifying therapies for autoimmune and inflammatory diseases. Its lead candidate, MTX-101, is a bispecific autoimmune checkpoint inhibitor planned for IND submission and a Phase 1 first-in-human trial in early 2024. An additional cytokine-based CD8 Treg network modulator is in preclinical development. The company is led by President and CEO Katie Fanning. Mozart intends to use the new funding to advance MTX-101 into human trials and to support pipeline expansion. Financially, the company expanded its Series A with a $25M extension, bringing total capital raised to $80M. Mozart Therapeutics is a Seattle biotech developing compounds that boost regulatory CD8 T cells to quell overactive immune responses in celiac disease and other autoimmune and inflammatory conditions. Its lead compound aims to increase activity of regulatory CD8 T cells and move through preclinical studies into human testing, with celiac disease trials expected to start in 2024. The company is also building bispecific compounds that bind regulatory CD8 T cells and inhibit the KIR brake, and it has additional compounds targeting different surface receptors. Programs build on research from co-founder Mark Davis’s lab at Stanford, and Mozart believes the approach may apply to type 1 diabetes and inflammatory bowel disease as well. Leadership includes CEO Katie Fanning, CSO Kristine Swiderek, and VP Courtney Crane; the roughly 13-person company plans to expand hires in research and product development. Mozart operates out of lab space near Seattle’s waterfront and raised capital to advance its lead program toward human trials.

Participated · Series A · Mar 2023

Curreio is a biotechnology company that provides Cryo‑Electron Microscopy (Cryo‑EM) structural‑analysis technology to accelerate drug discovery. The company determines high‑resolution structures of disease target proteins and ligand complexes, with particular strength on integral membrane protein families. Over the past three years Curreio has worked on more than 20 protein targets and solved structures for over 80% of them; roughly 70% of targets were integral membrane proteins. It integrates Cryo‑EM outputs with AI‑driven computational chemistry to increase hit rates while lowering R&D time and cost, and currently has four ongoing R&D projects. The team reports having extended its platform to analyze lower‑molecular‑weight targets (approximately 60 kDa) with ligands (publication in preparation). Curreio plans to use recent financing to further accelerate R&D programs and broaden its Cryo‑EM platform applicability.